Medios AG welcomes the new German Act on Strengthening Pharmaceutical Supply in Statutory Health Insurance (AMVSG)

  • German parliament passes the new German Act on Strengthening Pharmaceutical Supply in Statutory Health Insurance (AMVSG).
  • Public tendering on cytostatic drugs banned and abolition of exclusive cytostatic drug agreements will give insurance policyholders more freedom in the choice of their pharmacies.
  • Manfred Schneider, CEO of Medios AG says, “In the past, prices were the main thing that mattered in public tenders of the health insurance companies for cytostatic drugs. Now the focus is finally shifting to quality. The new law will improve not only the healthcare of patients but also the growth opportunities of Medios AG.”
  • Medios expects to further pursue its growth strategy in fiscal year 2017.

 

Berlin, March 10, 2017 – Medios AG, an expert pharmaceutical partner and solution provider in the Specialty Pharma segment, welcomes the new German Act on Strengthening Pharmaceutical Supply in Statutory Health Insurance (AMVSG), which was passed yesterday by the German parliament and is expected to enter into force in May 2017.

 

AMVSG will improve healthcare in Germany. It mostly affects people with chronic or genetic illnesses like cancer. Because these patients have a great need for cytostatic drugs that are delivered flexibly, safely, and locally, the law prohibits public tendering on cytostatic drugs and at the same time abolishes exclusive cytostatic drug agreements between health insurance companies and pharmacies. This would give insurance policyholders more freedom in the choice of their pharmacies.

 

Manfred Schneider, CEO of Medios AG: “In the past, prices were the main thing that mattered in public tenders of the health insurance companies for cytostatic drugs. Now the focus is finally shifting to quality. The new law will improve not only the healthcare of patients but also the growth opportunities of Medios AG. As a leading expert partner and solution provider for Specialty Pharma, we establish the benchmarks for personalized medicine. Thanks to our many years of experience and our comprehensive network, we are able to efficiently produce for example individualised cytostatic infusions while providing high quality and leveraging scales of economy. In Berlin, the city with the lowest reimbursement prices, we already have a 30% market share.”

 

Thanks to high demand for personalized medicine, Medios grew significantly in fiscal year 2016. According to preliminary consolidated calculations (pro forma, IFRS), sales revenue for the corporate group increased by 78% year-over-year to EUR 160.5 million (prior year EUR 90.1 million), thus exceeding market expectations. The operating result (EBIT) climbed disproportionately by 100.4% to EUR 5.67 million (prior year EUR 2.83 million). This improved profitability as the EBIT margin rose to 3.53% (prior year 3.14%).

 

For fiscal year 2017, the Management Board of Medios expects to further pursue its growth strategy due to market opportunities developing in the area of personalized medicine and regulatory actions related to AMVSG.

 

About Medios AG

Medios AG positions itself – along with its sister companies Medios Pharma, Medios Manufaktur and Medios Digital – as a competence partner and solution provider for the Specialty Pharma sector. Medios AG interconnects individual actors within the market and turns them into co-operating partners. It is our goal to guarantee best possible pharmaceutical care for patients while providing our partners and clients with integrated solutions along the supply chain. Specialty Pharma medicine are pharmaceuticals for patients with rare and chronic diseases such as certain cancer types and autoimmune / infectious diseases, which are time-consuming and cost-intensive to cure.

 

Contact

Kirchhoff Consult AG
Nikolaus Hammerschmidt
Herrengraben 1
20459 Hamburg
Telefon: +49 40 60918618
Fax: +49 60918660
E-mail: nikolaus.hammerschmidt@kirchhoff.de
www.kirchhoff.de

 

Disclaimer
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.